Establishment of the 1st world health organization international standards for human papillomavirus type 16 DNA and type 18 DNA

International Journal of Cancer

Volumn 126, Issue 12, 2010, Pages 2969-2983

  Wilkinson, Dianna E ^a   Baylis, Sally A ^a,e   Padley, David ^a   Heath, Alan B ^a   Ferguson, Morag ^a   Pagliusi, Sonia R ^b   Quint, Wim G ^c   Wheeler, Cosette M ^d  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c DDL DIAGNOSTIC LABORATORY   (Netherlands)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Assay standardization; HPV DNA; WHO international standards

Indexed keywords

VIRUS DNA;

ACCURACY; ARTICLE; FREEZE DRYING; GENE AMPLIFICATION; HEALTH CARE ORGANIZATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; NUCLEIC ACID ANALYSIS; PAPILLOMA VIRUS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STANDARD; VALIDATION STUDY; VIRUS DETECTION; VIRUS GENOME; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; DIAGNOSIS, MEASUREMENT AND ANALYSIS; GENETICS; HUMAN; INTERNATIONAL COOPERATION; MULTICENTER STUDY; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION;

DNA, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERNATIONAL COOPERATION; LABORATORY TECHNIQUES AND PROCEDURES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; WORLD HEALTH ORGANIZATION;

EID: 77951885316     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25039     Document Type: Article

References (37)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Pubitemid 29406813)
2. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384:260-265
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
4. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199: 926-935
5. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765
6. Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255
7. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170
8. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-944
9. Paavonen J, Naud P, Salmeron J, Wheeler C, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira J, Skinner S, Hedrick J, Jaisamrarn U, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374: 301-314
10. World Health Organization.WHO informal workshop: development of international HPV reference reagents, 2-4 September 2001. Florianópolis, Brazil, 2002.
11. World Health Organization.Assessment and harmonization of laboratory diagnostic procedures related to human papillomavirus vaccine research and development: report of a technical meeting, Heidelberg, Germany, 6-7 March, 2001.
12. World Health Organization.Department of immunization, vaccines and biologicals. Technical workshop on international collaborative studies on HPV reagents for laboratory diagnostic procedures: a progress report. 2004.
13. Quint WGV, Pagliusi SR, Lelie N, de Villiers E-M, Wheeler CM. The World Health Organization human papillomavirus DNAICSG. Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006;44:571-579
14. Auersperg N. Long-term cultivation of hypodiploid human tumor cells. J Natl Cancer Inst 1964;32:135-163
15. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999;76:149-158
16. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 2007;17: 1271-1277
17. Caballero OL, Villa LL, Simpson AJ. Low stringency-PCR (LS-PCR) allows entirely internally standardized DNA quantitation. Nucleic Acids Res 1995;23:192-193
18. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-423
19. Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissmann L, zur Hausen H, Luthra UK. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol 1992;36:239-245
20. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76 (Part 4):1057-1062
21. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003;112: 23-33. (Pubitemid 37338255)
22. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38: 357-361 (Pubitemid 30043317)
23. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, Park JS. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol 2003;89: 210-217 (Pubitemid 36457867)
24. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-1739
25. Lee YS, Rhim CC, Lee HN, Lee KH, Park JS, Namkoong SE. HPV status in sentinel nodes might be a prognostic factor in cervical cancer. Gynecol Oncol 2007;105:351-357
26. Park TC, Kim CJ, Koh YM, Lee KH, Yoon JH, Kim JH, Namkoong SE, Park JS. Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. DNA Cell Biol 2004;23:119-125 (Pubitemid 38221929)
27. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44: 504-512 (Pubitemid 43222244)
28. Tong SY, Lee YS, Park JS, Namkoong SE. Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. Int J Gynecol Cancer 2007; 17:1307-1313 (Pubitemid 350077356)
29. Tucker RA, Unger ER, Holloway BP, Swan DC. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. Mol Diagn 2001;6: 39-47.
30. van den Brule AJC, Pol R, Fransen- Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJF. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-787 (Pubitemid 34208623)
31. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 (Suppl 10): K29-41.
32. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101:88-99.
33. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357: 1579-1588 (Pubitemid 47598400)
34. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24 (Suppl 3): 171-177
35. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7: 547-555
36. Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV laboratory network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009;27: 337-347
37. WHO Expert Committee on Biological Standardization Fifty-fifth Report. WHO Technical Report Series, No. 932 2004.